Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: The REALIZE study

Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: The REALIZE study

BackgroundA tenosynovial giant cell tumor (TGCT) is a locally aggressive benign neoplasm arising from intra- or extra-articular tissue, categorized as localized (L-TGCT, solitary lesion) and diffuse (D-TGCT, multiple lesions) TGCT. Surgical excision is the mainstay of the treatment, and a high local...

Full description

Bibliographic Details
Main Authors: Akihiko Takeuchi, Makoto Endo, Akira Kawai, Yoshihiro Nishida, Ryu Terauchi, Akihiko Matsumine, Hisaki Aiba, Tomoki Nakamura, Susumu Tandai, Toshifumi Ozaki, Manabu Hoshi, Daiki Kayano, Miho Okuda, Norio Yamamoto, Katsuhiro Hayashi, Shinji Miwa, Kentaro Igarashi, Kenichi Yoshimura, Akihiro Nomura, Toshinori Murayama, Hiroyuki Tsuchiya
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
tenosynovial giant cell tumor (TGCT)
zaltoprofen
nonsteroid anti-flammatory drugs
randomizad controlled trial
clinical trial
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.900010/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.900010/full

Similar Items